GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Morphic Holding Inc (STU:31Y) » Definitions » Total Liabilities

Morphic Holding (STU:31Y) Total Liabilities : €17.65 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Morphic Holding Total Liabilities?

Morphic Holding's Total Liabilities for the quarter that ended in Mar. 2024 was €17.65 Mil.

Morphic Holding's quarterly Total Liabilities increased from Sep. 2023 (€19.15 Mil) to Dec. 2023 (€23.38 Mil) but then declined from Dec. 2023 (€23.38 Mil) to Mar. 2024 (€17.65 Mil).

Morphic Holding's annual Total Liabilities declined from Dec. 2021 (€79.29 Mil) to Dec. 2022 (€18.38 Mil) but then increased from Dec. 2022 (€18.38 Mil) to Dec. 2023 (€23.38 Mil).


Morphic Holding Total Liabilities Historical Data

The historical data trend for Morphic Holding's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Morphic Holding Total Liabilities Chart

Morphic Holding Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial 95.87 79.89 79.29 18.38 23.38

Morphic Holding Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.41 17.87 19.15 23.38 17.65

Morphic Holding Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Morphic Holding's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=22.72+(0.657+-0.00099999999999767
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=23.38

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=662.545-639.169
=23.38

Morphic Holding's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=16.294+(1.356+-1.9984014443253E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=17.65

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=628.144-610.494
=17.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Morphic Holding Total Liabilities Related Terms

Thank you for viewing the detailed overview of Morphic Holding's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Morphic Holding (STU:31Y) Business Description

Traded in Other Exchanges
Address
35 Gatehouse Drive, A2, Waltham, MA, USA, 02451
Morphic Holding Inc is a biopharmaceutical company applying its insights into integrins to discover and develop a pipeline of oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer.

Morphic Holding (STU:31Y) Headlines

No Headlines